Foradil

DRUG4 trials

Sponsors

Boehringer Ingelheim, Nemours Children's Clinic, Fundacio Privada Mon Clinic Barcelona

Conditions

Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveSafety of Long Acting Beta Agnoists

Phase 3

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

CompletedNCT00931385

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2009-06-30Updated: 2014-07-01

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

CompletedNCT00932646

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2009-06-30Updated: 2016-02-05

Phase 4

Effect of Gly16Arg Polymorphism in ADRB2 Gene on Asthma Control in Children Receiving Long Acting Beta Agonists

WithdrawnNCT01108627

Nemours Children's ClinicSafety of Long Acting Beta Agnoists

Start: 2010-10-31End: 2011-12-31Updated: 2023-05-26

ANTES B+ Clinical Trial

TerminatedNCT06282861

Fundacio Privada Mon Clinic BarcelonaChronic Obstructive Pulmonary Disease

Start: 2024-02-29End: 2025-01-23Updated: 2025-08-14

Related Papers

The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies.

2014-08-0934 citations